| Acrux Limited (ACR) ORDINARY FULLY PAID |
Health Care |
$5 |
Updated September Quarter Activities Statement and App4C
|
4 Nov 2025 9:20AM |
$0.015 |
$0.011 |
fallen by
26.67%
|
|
| Acrux Limited (ACR) ORDINARY FULLY PAID |
Health Care |
$5 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 Oct 2025 11:51AM |
$0.014 |
$0.011 |
fallen by
21.43%
|
|
ACR - Price-sensitive ASX Announcement
Full Release
Key Points
- Significant increase in quarterly profit share income.
- Received $3.040 million R&D Tax Incentive Rebate.
- Full repayment of Radium Capital advances.
- Net cash from operating activities: $1.652 million.
- Cash and cash equivalents at end of period: $0.722 million.
- Increased revenue from Nitroglycerin and Dapsone products.
- Focus on expanding to international markets and R&D pipeline evaluation.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Acrux Limited (ACR) ORDINARY FULLY PAID |
Health Care |
$5 |
Notice of Annual General Meeting/Proxy Form
|
24 Oct 2025 8:31AM |
$0.013 |
$0.011 |
fallen by
15.38%
|
|
| Acrux Limited (ACR) ORDINARY FULLY PAID |
Health Care |
$5 |
Notification of AGM date and nomination of directors
|
30 Sep 2025 3:30PM |
$0.014 |
$0.011 |
fallen by
21.43%
|
|
| Acrux Limited (ACR) ORDINARY FULLY PAID |
Health Care |
$5 |
Notification regarding unquoted securities - ACR
|
22 Sep 2025 9:58AM |
$0.015 |
$0.011 |
fallen by
26.67%
|
|
| Acrux Limited (ACR) ORDINARY FULLY PAID |
Health Care |
$5 |
Received $3.04m RDTI rebate for FY25
|
4 Sep 2025 8:24AM |
$0.013 |
$0.011 |
fallen by
15.38%
|
|
ACR - Price-sensitive ASX Announcement
Full Release
Key Points
- Acrux Limited announced receiving a $3.04 million R&D Tax Incentive rebate for FY25.
- The rebate was issued by the Australian Tax Office.
- Acrux repaid the short-term funding facility from Radium Capital.
- The RDTI reflects Acrux's commitment to Australian R&D investment.
- The rebate aligns with the government's vision for science-driven economic growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Acrux Limited (ACR) ORDINARY FULLY PAID |
Health Care |
$5 |
Received $3.04m RDTI rebate for FY25
|
4 Sep 2025 8:24AM |
$0.013 |
$0.011 |
fallen by
15.38%
|
|
ACR - Price-sensitive ASX Announcement
Full Release
Key Points
- Acrux Limited received a $3.04 million R&D Tax Incentive rebate.
- The rebate pertains to the fiscal year 2025.
- Funds were received from the Australian Tax Office.
- The rebate facilitated the repayment of a short-term funding facility with Radium Capital.
- The R&D Tax Incentive is an Australian Federal Government program.
- Acrux focuses on research and development to generate future commercial income.
- The announcement was authorized by the Board of Acrux Limited.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Acrux Limited (ACR) ORDINARY FULLY PAID |
Health Care |
$5 |
Appendix 4G and Corporate Governance Statement FY25
|
29 Aug 2025 8:58AM |
$0.015 |
$0.011 |
fallen by
26.67%
|
|
| Acrux Limited (ACR) ORDINARY FULLY PAID |
Health Care |
$5 |
Appendix 4E and Full Year Statutory Accounts FY25
|
29 Aug 2025 8:57AM |
$0.015 |
$0.011 |
fallen by
26.67%
|
|
ACR - Price-sensitive ASX Announcement
Full Release
Key Points
- Total revenue decreased by 44% to AUD 4,528,000.
- Net loss attributable to members increased by 2% to AUD 5,945,000.
- New US product launches include Nitroglycerine 0.4% Ointment and Dapsone Gel, 7.5%.
- Capital raising activities generated net proceeds of AUD 3,394,000.
- Agreement with Servacure Trading for product distribution in Saudi Arabia.
- Focus on US market and international expansion.
- Short term funding obtained under RDTI funding arrangement.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Acrux Limited (ACR) ORDINARY FULLY PAID |
Health Care |
$5 |
Licensing partnership in Saudi Arabia for Dapsone 5%, Gel
|
31 Jul 2025 9:01AM |
$0.018 |
$0.011 |
fallen by
38.89%
|
|
ACR - Price-sensitive ASX Announcement
Full Release
Key Points
- Acrux Limited has entered a licensing partnership in Saudi Arabia for Dapsone 5% Gel.
- The agreement provides exclusive rights to a Saudi partner for registration, marketing, and distribution.
- Dapsone 5% Gel is indicated for the treatment of acne vulgaris.
- Acrux will manufacture and supply the product.
- The Saudi partner will handle regulatory submissions and commercialization.
- The partnership supports Acrux's strategy to expand internationally.
- This deal is expected to maximize the value of Acrux's product portfolio.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Acrux Limited (ACR) ORDINARY FULLY PAID |
Health Care |
$5 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Jul 2025 9:03AM |
$0.018 |
$0.011 |
fallen by
38.89%
|
|
ACR - Price-sensitive ASX Announcement
Full Release
Key Points
- Acrux Limited released its Quarterly Activities and Appendix 4C Cash Flow Report for the quarter ended 31 March 2024.
- The company is advancing its portfolio of topical and transdermal pharmaceutical products.
- Acrux made regulatory submissions in the US and other markets during the quarter.
- Development of pipeline products remained a focus, with progress on multiple projects.
- The company maintained ongoing relationships with commercial and development partners.
- Cash flow summary included research and development expenses, receipts from customers, and other operating costs.
- Acrux reported its cash position and financial outlook remains stable.
- The company continues to focus on regulatory milestones and commercial expansion.
- Management is committed to prudent financial management as it seeks to grow its diversified pharmaceutical portfolio.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Acrux Limited (ACR) ORDINARY FULLY PAID |
Health Care |
$5 |
Receipt of second advance for FY25 R&D Tax Incentive
|
3 Jul 2025 9:29AM |
$0.018 |
$0.011 |
fallen by
38.89%
|
|
ACR - Price-sensitive ASX Announcement
Full Release
Key Points
- Acrux Limited received a second advance for the FY25 R&D Tax Incentive.
- The advance was facilitated by Radium Capital.
- Funds will be used to support ongoing R&D programs.
- The announcement is made in line with ASX listing rules.
- Shareholders are updated on funding and R&D progress.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Acrux Limited (ACR) ORDINARY FULLY PAID |
Health Care |
$5 |
Notification of cessation of securities - ACR
|
3 Jul 2025 9:24AM |
$0.018 |
$0.011 |
fallen by
38.89%
|
|
| Acrux Limited (ACR) ORDINARY FULLY PAID |
Health Care |
$5 |
Application for quotation of securities - ACR
|
3 Jul 2025 9:23AM |
$0.018 |
$0.011 |
fallen by
38.89%
|
|
| Acrux Limited (ACR) ORDINARY FULLY PAID |
Health Care |
$5 |
Change in substantial holding
|
30 Jun 2025 2:58PM |
$0.017 |
$0.011 |
fallen by
35.29%
|
|
| Acrux Limited (ACR) ORDINARY FULLY PAID |
Health Care |
$5 |
App 3Z, Kotsanis
|
2 Jun 2025 9:05AM |
$0.023 |
$0.011 |
fallen by
52.17%
|
|
| Acrux Limited (ACR) ORDINARY FULLY PAID |
Health Care |
$5 |
App 3X, Warmbrunn
|
2 Jun 2025 9:05AM |
$0.023 |
$0.011 |
fallen by
52.17%
|
|
| Acrux Limited (ACR) ORDINARY FULLY PAID |
Health Care |
$5 |
Appendix 3Y Brumley
|
23 May 2025 9:11AM |
$0.023 |
$0.011 |
fallen by
52.17%
|
|
| Acrux Limited (ACR) ORDINARY FULLY PAID |
Health Care |
$5 |
Application for quotation of securities - ACR
|
23 May 2025 9:10AM |
$0.023 |
$0.011 |
fallen by
52.17%
|
|
| Acrux Limited (ACR) ORDINARY FULLY PAID |
Health Care |
$5 |
Notification of cessation of securities - ACR
|
23 May 2025 9:05AM |
$0.023 |
$0.011 |
fallen by
52.17%
|
|
| Acrux Limited (ACR) ORDINARY FULLY PAID |
Health Care |
$5 |
Dapsone 7.5%, Gel launched in the United States
|
9 May 2025 8:33AM |
$0.023 |
$0.011 |
fallen by
52.17%
|
|
ACR - Price-sensitive ASX Announcement
Full Release
Key Points
- Acrux Limited announced the launch of Dapsone 7.5% Gel in the United States.
- Dapsone 7.5% Gel is a generic version of the branded product ACZONE® Gel, 7.5%.
- The product is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.
- The launch follows the approval from the U.S. Food and Drug Administration (FDA) for Acrux’s Abbreviated New Drug Application (ANDA) for Dapsone 7.5% Gel.
- The company expects the launch to expand its dermatology portfolio and strengthen its presence in the U.S. market.
- Acrux is focused on developing and commercializing topically applied pharmaceutical products.
- The U.S. market for Dapsone 7.5% Gel was estimated to be more than US$100 million per annum.
- Acrux’s CEO highlighted the importance of the launch as a significant milestone for the company’s strategy.
- Acrux plans to continue developing a range of generic dermatology products.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Acrux Limited (ACR) ORDINARY FULLY PAID |
Health Care |
$5 |
Acrux CEO and Managing Director appointment
|
7 May 2025 9:12AM |
$0.023 |
$0.011 |
fallen by
52.17%
|
|
ACR - Price-sensitive ASX Announcement
Full Release
Key Points
- Acrux Limited appoints Michael Kotsanis as CEO and Managing Director effective July 1, 2024.
- The Board highlights Mr. Kotsanis’s extensive experience and leadership in the pharmaceutical sector.
- Outgoing CEO will assist with the transition and continue offering strategic advice.
- The Board expresses gratitude for the outgoing CEO's service and achievements at Acrux.
- The appointment is part of Acrux’s ongoing commitment to growth and leadership strength.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Acrux Limited (ACR) ORDINARY FULLY PAID |
Health Care |
$5 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Apr 2025 10:03AM |
$0.023 |
$0.011 |
fallen by
52.17%
|
|
ACR - Price-sensitive ASX Announcement
Full Release
Key Points
- Acrux Limited reported its Quarterly Activities and Appendix 4C Cash Flow for the quarter ended 31 March 2024.
- Product development continued across dermatology, oncology, and hormonal product programs.
- FDA review ongoing for lidocaine topical solution.
- Cash receipts from customers totaled $1.5 million for the quarter.
- Net cash outflows from operating activities were $2.5 million, mainly due to R&D spending.
- Closing cash balance was $8.2 million at the end of the quarter.
- Company remains focused on progressing its product pipeline and partnership discussions.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Acrux Limited (ACR) ORDINARY FULLY PAID |
Health Care |
$5 |
Details of Share Registry address
|
9 Apr 2025 12:18PM |
$0.025 |
$0.011 |
fallen by
56%
|
|
| Acrux Limited (ACR) ORDINARY FULLY PAID |
Health Care |
$5 |
Appendix 3Y Dobinson
|
4 Apr 2025 9:11AM |
$0.023 |
$0.011 |
fallen by
52.17%
|
|